

ANNEX 16

Haemophilia Directors for Scotland and Northern IrelandNotes of Meeting

1990

Monday 26th February at 11.00a.m.

Department of Medicine, Royal Infirmary, Glasgow.

Present: Dr. A. Hepplestone  
 Dr. G.D.O. Lowe (Chairman)  
 Dr. C.A. Ludlam  
 Dr. T. Taylor

Apologies from: Dr. A.A. Dawson  
 Dr. B. Gibson  
 Dr. E.E. Mayne

1. Review of Factor VIII usage for 1989-90 financial year indicates that the totals (millions units) will be approximately as follows:

	<u>NHS</u>	<u>Commercial</u>	<u>Total</u>
Aberdeen	0.5	-	0.5
Dundee	0.5	-	0.5
Edinburgh	1.8	0.5	2.3
Glasgow (Glasgow RI & Yorkhill)	4.4	0.6	5.0
Inverness	0.3	-	0.3
			<u>8.6</u>

2. Allocations of Z8 for 1990/91

After discussion we recommended allocations for financial year 1990/91 as follows:

	1990/91	(1989/90)
Aberdeen	0.6	(0.7)
Dundee	0.6	(0.6)
Edinburgh	2.1	(2.0)
Glasgow	4.3	(4.F)
Inverness	0.4	(0.4)
	<u>8.0</u>	<u>(8.0)</u>

These were agreed subject to ratification of Aberdeen's allocation of 0.6M units.

### 3. Recommended Products

The draft of the Regional Directors document on Recommended Products was discussed. It is anticipated that the final version will be agreed and issued within the near future.

As factor VIII concentrate is recommended in place of cryoprecipitate for treating VWD (unless DDAVP is indicated in preference to a blood product or factor VIII is not haemostatic when the use of cryoprecipitate should be considered) we considered it reasonable that each Haemophilia Centre should hold a stock of NHS 8Y factor VIII concentrate (as Z8 is ineffective in many patients).

For East Coast Centres it was considered that a stock of 15,000 units of 8Y would be reasonable for emergency use. Dr. Ludlam to arrange redistribution of 8Y from Edinburgh with cross charging between Health Boards. Edinburgh also to hold stock of Monoclote P, Hyate C and Feiba which could be drawn upon emergency (particularly for East Coast Centres). Dr. Ludlam to discuss with R.I.E. Pharmacy.

### 4. Review of likely factor VIII use 1990-1995

We agreed that there were many unpredictable factors which might influence annual usage (e.g. Aledort joint study) during the next 5 years. Over the past 15 years use has increased by approximately 10% per annum. We considered that this would be a reasonable estimate starting from a base of 10M units at the beginning of the financial year 1989/90.

### 5. Audit

There was unanimity that audit should be promoted. The possibility of Directors visiting other Centres was agreed to be a useful way to carry out this activity. Dr. Lowe is to draft a brief paper for circulation. Dr. Ludlam to enquire whether Lothian Health Board would pay his expenses to travel (if there is agreement this can be used as a precedent for applications to other Health Boards).

### 6. Hepatitis C Tests

At a recent meeting of the Regional Haemophilia Centre Directors AIDS Committee a representative of the Medical Defence Organisation was quoted as considering that hepatitis C testing could be undertaken on the same basis as other LFT's (i.e. HIV type counselling was not necessary).

7. Next Meeting

Monday 23rd April at 11.00a.m. in the Haemophilia Centre,  
Edinburgh.